Evidence map›Paper›PMID 39147820›Full record

ArticleScientific reports2024

Entinostat as a combinatorial therapeutic for rhabdomyosarcoma.

Shefali Chauhan, Emily Lian, Iman Habib, Qianqian Liu, Nicole M Anders, Megan M Bugg, Noah C Federman, Joel M Reid, Clinton F Stewart, Tristan Cates and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shefali Chauhan *Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA.
Emily Lian *Children's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA.
Iman HabibChampions Oncology, Rockville, MD, 20850, USA.
Qianqian LiuDepartment of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, USA.
Nicole M AndersDepartment of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, 21231, USA.
Megan M BuggChildren's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA.
Noah C FedermanJonsson Comprehensive Cancer Center, University of California Los Ángeles, Los Angeles, CA, USA.
Joel M ReidMayo Clinic Comprehensive Cancer Center, Rochester, MN, 55905, USA.
Clinton F StewartPharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.
Tristan CatesChampions Oncology, Rockville, MD, 20850, USA.
Joel E MichalekDepartment of Epidemiology and Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, USA.
Charles KellerChildren's Cancer Therapy Development Institute, 9025 NE Von Neumann Drive Ste 110, Hillsboro, OR, 97006, USA. charles@cc-tdi.org.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcomaR01CA258720 · NCI · CHILDREN'S CANCER THERAPY DEVELOP/INST · PI KELLER, CHARLES · 2021 to 2025
$1.5M
1150 SMARCA4 R01 1150NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA258720
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. For the alveolar subtype (ARMS), the presence of the PAX3::FOXO1 fusion gene and/or metastases are strong predictors of poor outcome. Metastatic PAX3::FOXO1

Indexed as

BenzamidesPyridinesRhabdomyosarcomaXenograft Model Antitumor AssaysAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorHistone Deacetylase InhibitorsHumansMiceBenzamidesentinostatHistone Deacetylase InhibitorsPyridinesAlveolar rhabdomyosarcomaEmbryonal rhabdomyosarcomaEntinostatHDAC inhibitorMocetinostatRhabdomyosarcoma

Identifiers

PMID39147820
PMCPMC11327338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.